In part, the lack of research in "non-profitable" infectious diseases occurring in underprivileged countries has left threats like Ebola largely unaddressed. In addition, inequalities within the system of international scientific collaboration have hindered African researchers from leading the way against diseases ravaging their continent.
At just 20-years-old, Brynn has several serious chronic health conditions, one of which requires her to be one of the only people in the world to have a 24/7 Benadryl intravenous drip. But even though I've never met Brynn in real life, from miles and miles away I can feel the warmth, brilliance and hope that she is giving the world.
The crisis of Ebola virus disease in West Africa, at this writing, continues to deepen, with the World Health Organization now reporting more than 3,600 cases, and deaths exceeding 1,800. And yet, despite the headlines and the notes of alarm, Ebola as a research topic remains a comparatively limited presence in the scientific literature.
Cancer, Alzheimer's, ALS, multiple sclerosis, Parkinson's, and painful, chronic conditions such as rheumatoid arthritis and Crohn's disease will only be overcome if we, as a nation, have the will and commitment to once again make funding the type of essential research that led to the eradication of polio in the U.S. such a high national priority.
If we've read evidence supporting our management decisions, let's own it by truly referring to the literature. But if we are only vaguely aware of research that supports a questioned decision, without first taking time to read the evidence and/or supporting editorials and guidelines, let us not sugarcoat our lack of due diligence.